GlassScriptPhysician profile
David A Edmondson
NPI 1124079033
$207,206.51
in general payments reported to CMS, 2019-2025
15 companies · $37K in 2025
The $37K reported for 2025 was more than what 94% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,521 · 2020: $774 · 2021: $6,257 · 2022: $50K · 2023: $52K · 2024: $55K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $129K · Travel and Lodging: $8,187 · Consulting Fee: $4,165 · Food and Beverage: $3,282 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,950.00 |
| Travel and Lodging | $8,186.91 |
| Consulting Fee | $4,165.00 |
| Food and Beverage | $3,282.06 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $181,558.00 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Amgen INC. | $21,178.22 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $3,210.54 | 2019-2025 | Dupixent |
| Jubilant Hollisterstier LLC | $1,000.00 | 2023 | |
| Genentech USA, INC. | $67.16 | 2021-2024 | Xolair |
| Acclarent, INC | $33.14 | 2022 | |
| Shire North American Group INC | $27.55 | 2019 | |
| Csl Behring | $19.71 | 2025 | Andembry |
| Aerin Medical INC. | $19.07 | 2024 | |
| Octapharma USA, INC. | $17.41 | 2024 | Cutaquig |
| Alk-Abello, INC | $16.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.99 | 2024 | Cuvitru |
| Grifols USA, LLC | $14.13 | 2024 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Edmondson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.